SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001520138-21-000255
Filing Date
2021-05-10
Accepted
2021-05-10 16:16:18
Documents
50
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR PERIOD ENDING MARCH 31, 2021 bivi-20210331_10q.htm   iXBRL 10-Q 608161
2 EXHIBIT 31.1 bivi-20210331_10qex31z1.htm EX-31.1 12091
3 EXHIBIT 31.2 bivi-20210331_10qex31z2.htm EX-31.2 12221
4 EXHIBIT 32.1 bivi-20210331_10qex32z1.htm EX-32.1 5243
5 EXHIBIT 32.2 bivi-20210331_10qex32z2.htm EX-32.2 5129
  Complete submission text file 0001520138-21-000255.txt   3360638

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bivi-20210331.xsd EX-101.SCH 29734
7 XBRL CALCULATION FILE bivi-20210331_cal.xml EX-101.CAL 30480
8 XBRL DEFINITION FILE bivi-20210331_def.xml EX-101.DEF 116843
9 XBRL LABEL FILE bivi-20210331_lab.xml EX-101.LAB 235278
10 XBRL PRESENTATION FILE bivi-20210331_pre.xml EX-101.PRE 206122
11 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20210331_10q_htm.xml XML 489665
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

IRS No.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39015 | Film No.: 21907422
SIC: 2834 Pharmaceutical Preparations